Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 23Terminated 8Recruiting 3Withdrawn 2Active not recruiting 2Unknown 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 25Lung Neoplasms 8Mesothelioma, Malignant 4Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Advanced Non-squamous Non-small-cell Lung Cancer 2Uterine Cervical Neoplasms 1Solitary Fibrous Tumor, Pleural 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Head and Neck Neoplasms 1Glioma 1Esophagogastric Cancer 1Colorectal Neoplasms 1Advanced Solid Tumors 1

Interventions

Pemetrexed 2Cisplatin 2talazoparib 1poly ICLC 1pembrolizumab 1milademetan 1atezolizumab 1Vorinostat 1Talc 1Surveys and Questionnaires 1Cryosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Mesothelioma × Pemetrexed × Clear all
NCT00668499 2014-05-21

A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

University of Southern California

Phase 1/2 Withdrawn
Other solid neoplasmThoracic

Mesothelioma

NCT01353482 2012-03-22

MESO-02

University College, London

Phase 1/2 Withdrawn
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡